Your browser doesn't support javascript.
loading
Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.
Grasselli, J; Elez, E; Caratù, G; Matito, J; Santos, C; Macarulla, T; Vidal, J; Garcia, M; Viéitez, J M; Paéz, D; Falcó, E; Lopez Lopez, C; Aranda, E; Jones, F; Sikri, V; Nuciforo, P; Fasani, R; Tabernero, J; Montagut, C; Azuara, D; Dienstmann, R; Salazar, R; Vivancos, A.
Afiliação
  • Grasselli J; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona.
  • Elez E; Department of Medical Oncology, Catalan Institute of Oncology, Universitat de Barcelona, L'Hospitalet, Barcelona.
  • Caratù G; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona.
  • Matito J; Department of Medical Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona.
  • Santos C; Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona.
  • Macarulla T; Cancer Genomics Group, Vall d'Hebron Institute of Oncology, Barcelona.
  • Vidal J; Department of Medical Oncology, Catalan Institute of Oncology, Universitat de Barcelona, L'Hospitalet, Barcelona.
  • Garcia M; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona.
  • Viéitez JM; Department of Medical Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona.
  • Paéz D; Department of Medical Oncology, Del Mar University Hospital, Barcelona.
  • Falcó E; Department of Medical Oncology, Catalan Institute of Oncology, Universitat de Barcelona, L'Hospitalet, Barcelona.
  • Lopez Lopez C; Department of Medical Oncology, Asturias University Hospital, Oviedo.
  • Aranda E; Department of Medical Oncology, Santa Creu i Sant Pau University Hospital, Barcelona.
  • Jones F; Department of Medical Oncology, Son Llatzer University Hospital, Palma de Mallorca.
  • Sikri V; Department of Medical Oncology, Marques de Valdecilla University Hospital, Santander.
  • Nuciforo P; Department of Medical Oncology, Reina Sofía University Hospital, Córdoba, Spain.
  • Fasani R; Sysmex Inostics, Mundelein, USA.
  • Tabernero J; Sysmex Inostics, Mundelein, USA.
  • Montagut C; Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona.
  • Azuara D; Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona.
  • Dienstmann R; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona.
  • Salazar R; Department of Medical Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona.
  • Vivancos A; Department of Medical Oncology, Del Mar University Hospital, Barcelona.
Ann Oncol ; 28(6): 1294-1301, 2017 Jun 01.
Article em En | MEDLINE | ID: mdl-28368441
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Genes ras / Receptores ErbB / Mutação Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Genes ras / Receptores ErbB / Mutação Tipo de estudo: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article